Phase 4 N=61 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
Acne Vulgaris
Primary: Adherence to Treatment — 64; 38; 28; 52 Percent of prescribed doses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Treatment of Older Adults With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Overall Survival at One Year — 19 Participants
N/A N=24 Hypnosis in Pain Management, Anxiety and Depression in Oncological Patients
Pain · Depression Anxiety Disorder
Primary: Change of Pain Score in the Visual Analogue Scale — 7.33; 5.58; 3.67; 5.67 units on a scale — p=0.034
Phase 2 N=29 Intranasal Oxytocin and Learning in Autism
Autism Spectrum Disorders
Primary: Change From Baseline to Post-testing (After Max. 12 Days) on the Part/Whole Identity Test (LFI Skills Battery) — 3.30; 3.17 change in percent correct
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
N/A N=781 Comparison of Glottic Views and Intubation Times in the Supine and 25 Degree Back-up Positions
Elective Surgical Patients
Primary: The Best Glottic View Obtained During Laryngoscopy — 186; 228; 163; 151 participants — p=>0.05
Phase 3 N=875 Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
HBeAg-positive Chronic Hepatitis B
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 — 63.9; 66.8 percentage of participants
Phase 2 N=15 Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
Chemotherapy Induced Nausea and Vomiting
Primary: Feasibility of Recruitment and Data Collection. — 70.4 percentage of completed forms
N/A N=75 Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
Phase 2 N=10 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Breast Cancer
Primary: Clinical Benefit Rate — 0; 0; 3; 7 Participants
Phase 2 N=16 Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
Sleep Apnea, Obstructive
Primary: Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility — -5.2; -1.9; -2.2; -0.7 cm H2O — p=0.049
N/A N=18 Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell
Phase 3 N=426 Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
HBeAg-negative Chronic Hepatitis B
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL — 94.0; 92.9 Percentage of participants
N/A N=4,100 An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24) — 52.1; 49.4; 46.6; 50.5 percentage of…
N/A N=180 A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions